Caribou Biosciences CRBU 深 滬
等待開盤 11-06 09:30:00 美东时间
2.19
+0.020
+0.92%
華盛通- 最 高2.29
- 今 開2.28
- 成交量 212.12万股
- 最 低 2.09
- 昨 收 2.17
- 總市值 2.04亿
- 52周最高 3.535
- 市盈率 靜 --
- 換手率 2.28%
- 52周最低 0.66
- 委 比 32.43%
- 總股本 9312.32万
- 歷史最高 32.645
- 量 比 0.14
- 振 幅 9.22%
- 歷史最低 0.66
- 每 手 1
- 風險率 0.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
今天 09:55
3 Penny Stocks to Watch Now, 11/4/25
Generation Essentials Group, Phio Pharmaceuticals, and Caribou Biosciences are ...
11-04 23:49
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
Caribou Biosciences will hold a webcast on November 3, 2025, at 8:00 am ET, to present new data from its ANTLER phase 1 trial for vispacabtagene regedleucel (vispa-cel), an allogeneic anti-CD19 CAR-T therapy for relapsed or refractory B cell non-Hodgkin lymphoma, and initial data from its CaMMouflage phase 1 trial for CB-011, an allogeneic anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma. The company will also discuss plans for...
11-02 21:00
CORRECTION: Caribou Biosciences Q2 Adj. EPS $(0.35) Beats $(0.39) Estimate, Sales $2.667M Beat $2.465M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.39) by 9.09 percent. This is a 16.67 percent increase over losses of $(0.42) per share
08-13 06:33
Caribou Biosciences Regains Nasdaq Compliance
Caribou Biosciences ( ($CRBU) ) just unveiled an update. On June 18, 2025, Cari...
06-24 02:41
Caribou Biosciences Confirms Director Elections and Auditor
The latest announcement is out from Caribou Biosciences ( ($CRBU) ). On June 12...
06-14 04:50
Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference
Caribou Biosciences, Inc., a CRISPR genome-editing company, announced that its CEO, Rachel Haurwitz, PhD, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th at 9:20 AM EDT. For more information and to access the webcast, visit the Events page on Caribou’s website, where webcasts will be available for at least 30 days post-event.
05-28 20:00
艾伯维挥起拳头
转自：新康界 艾伯维，作为昔日药王的拥有者，面临专利悬崖压境，举起拳头挥向新战场！ 自免领域并购提速、神经科学重金押注、ADC赛道连出重拳，艾伯维以一场战略大突...
05-25 10:59
Caribou Biosciences Q1 EPS $(0.43) Beats $(0.44) Estimate, Sales $2.35M Beat $1.75M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.44) by 2.27 percent. This is a 6.52 percent increase over losses of $(0.46) per share from
05-09 04:50
